You are here » Home » Companies » Company Overview » Parmax Pharma Ltd

Parmax Pharma Ltd.

BSE: 540359 Sector: Health care
NSE: N.A. ISIN Code: INE240T01014
BSE 00:00 | 25 Nov 33.70 -2.25
(-6.26%)
OPEN

36.95

HIGH

36.95

LOW

33.70

NSE 05:30 | 01 Jan Parmax Pharma Ltd
OPEN 36.95
PREVIOUS CLOSE 35.95
VOLUME 1762
52-Week high 70.90
52-Week low 26.35
P/E
Mkt Cap.(Rs cr) 13
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 36.95
CLOSE 35.95
VOLUME 1762
52-Week high 70.90
52-Week low 26.35
P/E
Mkt Cap.(Rs cr) 13
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Parmax Pharma Ltd. (PARMAXPHARMA) - Chairman Speech

Company chairman speech

Dear Shareholders

Please allow me to begin by paying tribute to Late Shri Alkesh Gosalia our legendaryand visionary Managing Director who was the helm of affairs of the Company for almost oneand half decade. I strongly believe that the rich legacy left behind by him and the strongwork culture embedded with deep familial values that he built during his tenure will keepinspiring us and give us enough resilience to bounce back from any adversity in future.

Also I wish to take this opportunity to express my sincere gratitude to Board Membersfor appointing me to the position left vacant by the untimely demise of Shri AlkeshGosalia.

For the Company through the year the top priority was to ensure the wellbeing of ouremployees. It is our belief that a high performing organisation is defined by empatheticmanagement of people and talent. It is this unwavering commitment to the 'People First'philosophy and this value at the core of all our business strategy which has helpedCompany to overcome the two waves of pandemic. The leadership remained committed to thisemployee centric vision even during pandemic; This fundamental value has also inspiredbusiness resilience.

Despite the challenging economic environment your Company delivered Gross Sales of Rs.26.29 Crore in the fiscal year 2020-21 with increase of ~ 25%. as compared to last year.Overall the business was impacted by Covid-19 induced lockdowns and restrictions duringthe year but we continue to remain fully committed to creating long term value for ourshareholders.

Finally I am very proud of how the Parmax leadership team has stayed focused on thebusiness and together delivered a relatively stable financial and operational performancethis year. I would like to again acknowledge the efforts of each and every one of our teammembers for their adaptability resilience and contribution during an exceptionallydifficult year.

Lastly I would like to thank all our business partners and shareholders for theircontinued support. With our clear strategic direction Parmax is well positioned to driveprofitable growth in the coming years.

Warm regards

Umang Gosalia

Managing Director's Message

.